Who is the manufacturer of Ebglyss (Lebrikizumab)?

Ebglyss (Lebrikizumab) is a novel subcutaneous recombinant humanized IgG4 anti-IL-13 monoclonal antibody jointly developed by Almirall S.A and Eli Lilly and Company. The main indication for this drug is the treatment of atopic dermatitis (eczema), especially in moderate to severe cases.

Lebrikizumab is an IL-13 antagonist. It is understood to inhibit IL-13 by neutralizing the cytokine and preventing the binding and heterodimerization of the receptor subunits IL-13Rα1 and IL-4Rα. Ebglyss binds to IL-13 with high affinity and blocks downstream signaling, reducing inflammation, thereby helping to alleviate the symptoms of AD and improve the skin's barrier function.

Clinical studies with Ebglyss have shown that use of the drug can significantly improve symptoms of atopic dermatitis, particularly inflammation in eczema. It works by selectively inhibiting interleukin 13 (IL-13), thereby reducing the inflammatory response associated with the disease. Ebglyss offers a targeted approach to reducing the primary causes of inflammation in eczema, allowing patients to achieve longer-lasting symptom relief.

Ebglyss is only available by prescription, and treatment should be initiated by a doctor experienced in diagnosing and treating atopic dermatitis. It is available as a prefilled pen or prefilled syringe. Ebglyss can be used with other treatments for atopic dermatitis applied to the skin (i.e., topical corticosteroids or topical calcineurin inhibitors).

Ebglyss is administered as a relatively simple subcutaneous injection, usually in the thigh or abdomen, every other week for 16 weeks. Patients who respond to treatment can continue treatment with injections every four weeks. This feature improves drug compliance, thereby improving treatment effectiveness. With its approval in different regions, Lebrikizumab is expected to become one of the standard treatment options for patients with atopic dermatitis, helping them improve their quality of life.